Linked Life Data

17639750

Source:http://linkedlifedata.com/resource/pubmed/id/17639750

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2007-7-20
pubmed:abstractText
Perennial allergic rhinitis (PAR) can have a significant impact on a patient's quality of life. While allergen avoidance is the first line of management for PAR, complete avoidance is difficult. Therapeutic options available for PAR include intranasal corticosteroids (INS), H1-antihistamines, decongestants and local chromones, as well as immunotherapy. For mild symptoms, INS and antihistamines are the standard of care, whereas for moderate-to-severe PAR, INS are the preferred therapy due to their proven efficacy. Patient quality of life and therapy preference play a role in maintaining adherence to treatment.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0038-4348
pubmed:author
pubmed:issnType
Print
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
701-8
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Treatment options for the management of perennial allergic rhinitis, with a focus on intranasal corticosteroids.
pubmed:affiliation
Cabarrus Family Medicine Residency Program, Charlotte, NC 28226, USA. OzDoc@aol.com
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't